Diabetes mellitus heightens susceptibility to myocardial infarction (MI), contributing to elevated morbidity and mortality rates. Oxidative stress and cardiac apoptosis are recognized as primary contributors to diabetes-induced cardiovascular complications. We explored the protective effects of Azilsartan in streptozotocin-induced diabetic rats with isoproterenol- induced MI. Azilsartan pre-treatment led to a dose-dependent reduction in systolic, diastolic, and mean arterial pressures, with significant improvements in myocardial contractile function and decreased left ventricular end-diastolic pressure (LVEDP). Histopathological analysis revealed preserved cardiac morphology and reduced necrosis in Azilsartan- treated rats. Biochemical assays demonstrated restoration of cardiac injury markers and antioxidant levels. Azilsartan's cardioprotective effects may involve activation of the PPAR pathway. Combination therapies targeting PPAR and angiotensin II receptor blocker pathways represent a promising approach for managing cardiovascular complications in diabetes. Further research is warranted to elucidate Azilsartan's precise mechanisms of action and optimize treatment strategies.